performed H&E staining (Figure a and b was from identical area). 5 areas of normallooking lung parenchyma for each slide were randomly selected. The number of alveolar sac surrounded by string-like framework (FW) was counted. Area ratios of Pores of Kohn to each alveolar sac membrane surrounded by framework (PK) were calculated with images from the spots of interest (Figure c ). Image J was used for stack construction and measurement of images (Figure d) . Clinical data including pulmonary function test of patients was collected. Comparison of clinical data was performed with t test. Multilevel linear mixed model was used to evaluate differences of FW and PK and associations with clinical data. P values <.05 were considered significant.
Conclusions:
Although not organ specific, MASH1 is highly specific for NECs in lung cancers versus other lung phenotypes and may also be useful in discriminating NECs from other NETs in various types of cancers.
The Contribution of Second Generation Fluorescence In Situ Hybridization (FISH) To histopathologic and Immunophenotypic Analyses in the Diagnosis of Ambiguous Melanocytic Tumors (AMT)
Rami Al-Rohil, Jonathan Curry, Carlos Torres-Cabala, Doina Ivan, Roland Bassett, Victor Prieto, Michael T Tetzlaff Results: Based on a synthesis of histopathologic and IHC findings, cases were designated as "favor benign" (FB; n=15) or "favor malignant" in (FM n=15) by a consensus group of 5 dermatopathologists. FISH testing was positive in 2/15 FB lesions and 6/15 FM lesions. For all cases, the final diagnosis reflected the histopathologic and IHC consensus impression. The sensitivity of FISH for the diagnosis of melanoma in this series was 40% and the specificity was 87%. Univariate logistic regression models for a final diagnosis of melanoma showed that only elevated Ki-67 (>5%) significantly correlated with the diagnosis of melanoma (p=0.02); no other clinical, histopathologic or IHC parameter was significant. No clinical or pathologic variable correlated with FISH positivity, and there was no relationship between the FISH result and the final diagnosis (melanoma or nevus; p=0.21). Follow-up (range: 79-572 d) was available for 29 cases (14 benign/15 melanoma). Sentinel lymph node metastases were detected in only 4 cases: 2 FISH-negative melanomas and 2 FISH-positive melanomas. The histopathologic diagnosis of melanoma (versus nevus) correlated with subsequent metastasis (p=0.04), but FISH positivity did not correlate with the development of metastases (p=0.30).
Conclusions: Diagnosing AMTs requires a systematic assessment of histopathologic and IHC parameters. FISH negativity in a FB lesion is reassuring, but given the apparent low sensitivity, in the setting of AMTs, the results of FISH testing must be integrated into the constellation of findings-especially in a FM setting.
Recommendation for Pathologic Evaluation of Reduction Mammaplasty Specimens -A Prospective Study With Systematic Tissue Sampling
Abiy Ambaye, Andrew Goodwin, Susan MacLennan, Shelly Naud, Donald Weaver. University of Vermont, Burlington, VT. Background: Reduction mammoplasty (RMP) is a common procedure and was performed in 103,775 US patients in 2013. The reported incidence of occult breast cancer in RMP ranges from 0.06% to 12.4%. No standard pathology assessment for RMP exists. This study's objectives were to report the incidence of significant pathologic findings (SPF) in RMP specimens; to identify clinical risk factors for SPF; and to propose standard sampling for microscopic evaluation of RMP specimens. Design: All consecutive RMP specimens were prospectively examined to include a baseline gross examination and systematic microscopic sampling via rank-ordered tissue section sets (TSS). TSS-1 had 1 skin and 3 breast sections while TSS-2 and TSS-3 had 4 additional breast sections in each. The incidence of SPF was tabulated, as well as age, specimen weight, history of carcinoma, and preoperative mammogram results. Also examined were proliferative and non-proliferative changes as well as skin lesions. Results: 595 cases were evaluated, and SPF was present in 9.8% of patients. 83% of SPF was identified in TSS-1 and TSS-2 ( *All detected by frozen section **All except one was detected on first level H&E slide. The SLN on which a micrometastasis was detected on the deeper level was not sectioned at 2mm intervals at the time of grossing. H&E slides produced including multilevel recuts: 878 Level 1 H&E slides produced: 376 Additional H&E slides generated from multilevel recuts (potential savings): 502 Cost per H&E stained slide: $2.50 Cost savings of H&E stained slides: $1255.00 Technician savings: $796.00 Total potential savings: $2051.00 per 100 breast cases containing sentinel node resections. Conclusions: Multilevel recuts on SLNs did not help in the identification of macrometastasis. Additionally, all but 1 nodal micrometastasis, representing 0.36% of the 275 sentinel lymph nodes reviewed, were detected on the first H&E level. However the SLN in this case was not sectioned at 2mm. No additional slides would be required when the SLN is sectioned at 2 mm at grossing since such sampling would likely reveal the micrometastasis. Our pilot study does not support continuing to evaluate multilevel recuts on SLNs. The benefits did not outweigh the increased costs and resource requirements of the histopathology laboratory and pathologist's time. We anticipate that the benefits would be even greater when applied to daily workload in breast pathology in our institution.
Anion Gap Underestimated By Point-of-Care Testing in Diabetics and End Stage Renal Disease Patients
Tiffany Caza, Kelly Costello, Jean Sgroi, Matthew Elkins. SUNY Upstate Medical University, Syracuse, NY. Background: Point-of-care (POC) testing is a valuable resource, allowing rapid measurement of pH and electrolytes to assist clinical decision making for critically ill patients. In comparing POC and core lab measurements, we identified a discrepancy in 10.4% patients. As anion gap (AG) measurements provide important clues for determining the etiology of metabolic acidosis, we sought to identify whether a subset of patients is represented in the discrepancies to optimize use of POC testing in emergency departments. Design: Concurrent measurement of >1500 samples of serum pH and electrolytes using iSTAT POC device CHEM8 and Roche P800 platform in the core laboratory from 1/2011 to 2/2014 was performed. Anion gap (AG)was calculated by AG = Na -(Cl +TCO 2 ). Full chart review was done with the 44 patients with discrepant Cl and AG measurements and 45 controls where the calculated AG measurements were within -1 to +1. Statistical analysis was completed utilizing t-tests and ANOVA to determine differences between groups. A p value of <0.05 was considered significant. Results: Chloride levels in patients admitted with DKA or ESRD had a significant discrepancy between POC and core lab measurements (discrepant Cl difference +6 to +17 mmol/L, control Cl difference -5 to +4 mmol/L, p = 6.2 x 10 -27 ). This resulted in normalization of a high AG, with an inverse relationship between AG and Cl discrepancy. iSTAT pH values (blood gas cartridge) are concordant with core lab measurements. Patients were younger in the discrepant group compared to controls (45.8 y compared to 57.6 y, p=0.01). The number of medications taken was not a significant variable (mean control 6.7, discrepant 8.2). Secondary diagnoses of atrial fibrillation, CAD, and CVA were more common in controls, while patients in the discrepant group had an increased frequency of metabolic acidosis, type I or II diabetes mellitus, diabetic complications (gastroparesis, retinopathy, neuropathy), and vomiting. Use of exogenous insulin (50% vs 2%), ondansetron (28% vs 0%), gabapentin (18% vs 8%), and nephrolite (14% vs 4%) were increased in the discrepant group, while furosemide use was increased in controls. Conclusions: Chloride measurement by POC testing can be unreliable in a small cohort of patients, including those with DKA and ESRD. AG normalization by Cl discrepancy reduces identification of true AG metabolic acidosis and can result in delayed treatment. Therefore, caution should be taken in interpreting results of POC testing when the laboratory values do not seem to reflect the patient's condition.
Correlation of Atypical/Suspicious Rapid On-Site Fine Needle Aspiration Diagnoses With Final Diagnoses: An Institutional Experience With 154 Cases Over 3 Year Period
Michael Chaump, Navneet Narula, Rana Hoda, Tamar Giorgadze. Weill Cornell Medical College, New York, NY. Background: Rapid on-site evaluation (ROSE) of lung lesions is useful for adequacy assessment of fine needle aspirations (FNA). Our academic center implemented an early lung cancer screening program utilizing FNA for even small lung lesions, < 5mm, with suspicious radiology findings. In all cases, ROSE is performed to ensure sample adequacy for diagnosis and ancillary studies (immunocytochemical and molecular), with a minimal number of passes. Atypical/suspicious (ATY/SUSP) ROSE diagnoses trigger additional FNA passes for diagnostic purposes and for allocation of material for ancillary studies. In this study we correlate ATY/SUSP ROSE diagnoses with final cytological and histological findings. This to our knowledge, has thus far, not been reported. Design: All consecutive lung FNA with ATY/SUSP ROSE diagnoses over a 3-year period were retrospectively reviewed. Clinicopathological findings were documented. Two smears from each pass were prepared and stained with Diff-Quik (DQ) for ROSE and PAP stain for final. Residual material was submitted for cell block (CB). ROSE diagnosis was correlated with final cytological and histological diagnosis. Results: A total of 154 lung FNAs from 148 patients (56 men and 92 women; age range, 25-95 years; mean, 69.8). Average number of passes was 2 (range 1-8). Final cytological diagnosis for ATY/SUSP ROSE was ATY, 30; SUSP, 18; malignant, 98 [adenocarcinoma (ACa) , 68; squamous cell Ca, 12; neuroendocrine tumor, 6; non-small cell lung Ca, 5; Lymphoma, 1; Metastatic Ca, 6] and benign/reactive 8. Histology specimens were available in 106 (69%) cases. Cytohistological concordance rate was 96.2% (4 discordant cases, all seemingly attributable to sampling, rather than interpretaition issues).
Conclusions:
The final cytological diagnoses in the majority of ATY/SUSP ROSE diagnoses were lung ACa. This may reflect difficulties in diagnosing well-differentiated ACa (lepidic growth pattern) on DQ during ROSE, due to morphologic overlap with reactive pneumocytes. Nevertheless, ATY/SUSP ROSE in our study did not seem to affect patient care as additional passes triggered by ROSE led to diagnostic yield of malignancy in 98% of cases with a cytohistological concordance rate of 96.2%. Carol Cheung, John Garratt, C Blake Gilks, Jennifer Won, Jean-Claude Cutz, MingSound Tsao, Emina Torlakovic Background: Intra-chromosomal rearrangements involving the ALK gene are found in 3-5% of non-small cell lung cancers (NSCLCs). Crizotinib is a tyrosine kinase inhibitor that has been shown to prolong progression free survival in patients with advanced NSCLC harbouring ALK gene rearrangements. In Canada, ALK-1 immunohistochemistry (IHC) is used as a screening test prior to confi rmation by FISH. Design: CIQC has performed two ALK (Lung Ca) runs to date. Profi ciency testing (PT) samples included 32 previously characterized cases (IHC and FISH) from either Canadian ALK (CALK) project or samples from CIQC reference laboratories. The same design was used for both runs. 20 laboratories particpated in Run 1 and 22 in Run 2. Some laboratories participated in anticipation of future need and used the PT exercise as a part of test development and validation. The results of IHC testing were fi rst self reported using the CIQC TMA Scorer and then evaluated by expert assessment. FISH results were self-reported only. Participants also reported details about IHC and FISH protocols. Percent correct results and kappa-values were calculated for which >90% and > 0.80 were used as acceptable results respectively. Pass rate between the two runs and between different primary antibodies were compared. Results: Seven of 19 laboratories (37%) in Run 1 and 14 of 19 (74%) laboratories in Run 2 passed the CIQC PT criteria for IHC testing. The increase in pass rate for Run 2 was signifi cant (p=0.012, Fisher's Exact Test). The pass rate was signifi cantly higher for laboratories using 5A4 compared to other antibodies in both PT runs (p=0.004 in Run 1 and p=0.025 in Run 2, Chi-Square Test). All reported FISH results were correct. Conclusions: PT for IHC for rare diseases such as ALK-positive lung cancer is feasible but challenging. The academic nature of the CIQC program and collaboration on a national level facilitated the development of appropriate PT samples. Participating laboratories made use of the PT exercise to either confi rm that their testing was properly calibrated or to improve their protocols, which was confi med by achivement of signifi cantly better results in Run 2. They also used CIQC's PT program for new test development and optimization.
Developing ALK-1 Immunohistochemistry and In Situ Hybridization Proficiency Testing: Canadian Immunohistochemistry Quality Control (CIQC) Experience

Quantifying Pre-Signout and Post-Signout Pathologist Quality Assurance Activities
Carol Cheung, Emina Torlakovic, Runjan Chetty, Bayardo Perez-Ordonez. University Health Network, University of Toronto, Toronto, ON, Canada. Background: Although quality assurance (QA) activities in pathology are routine practice, the formal documentation of QA activities is largely focused on post-signout (postSO) correlations (eg. the interpretive accuracy of already issued reports). However, pre-signout (preSO) activities have more direct impact on the quality of reports and patient safety and may include reviewing patient charts, intradepartmental consultations, reviewing reports or slides from a previous procedure, etc. The growing requirement for documentation of "quality" has made it more important to quantify the work required for QA activities. Automatable Activity-Based Approach to Complexity Unity Scoring (AABACUS) is a recently published pathologist workload model, which may be well suited for translating laboratory information system (LIS)-documented QA activities into quantifi able workload. We present here results from the calendar year following the introduction preSO QA activities into our departmental LIS. Design: All QA activities for clinical cases documented in the departmental LIS were analyzed. Workload was calculated in complexity units using AABACUS. Results: A total of 121,259 clinical cases were assessed. QA activity was documented in 17% of cases; 13% of cases had preSO QA activities, and 4% had postSO QA activities. PreSO intradepartmental consultations were documented in 6% of cases, which represented 27% of all QA activities and 37% of all pre-SO QA activities. Review of the patient chart accounted for 3% of documented QA activities. Total documented QA activities accounted for 4.3% of overall departmental workload; specifi cally, preSO QA and postSO QA activities accounted for 3.7% and 0.6% of overall departmental workload. All documented QA activities accounted for 2.7 FTEs of work using relative benchmarking in AABACUS. Conclusions: Peer case reviews and other professional QA activities in pathology can be quantifi ed using the AABACUS workload model. The consistent documentation of QA activities by pathologists is a pre-requisite for the accuracy of results produced by AABACUS. PreSO QA activities, especially preSO intradepartmental consultations, represent a signifi cant component of LIS-documented pathologist QA activities in our institution; facilitating the documentation of such activities is an important consideration if expansion of QA programs is undertaken. Richard Colling, David Church, Juliet Carmichael, Lucinda Murphy, James East, Peter Risby, Rachel Kerr, Runjan Chetty, Lai Mun Wang. University of Oxford, Oxford, United Kingdom; University of Oxford, Oxford, United Kingdom; Oxford University Hospitals NHS Trust, Oxford, United Kingdom; University Health Network, Toronto, ON, Canada. Background: Lynch Syndrome (LS) accounts for 0.3-2.4% of colorectal cancers and is caused by germline mutations in mismatch repair (MMR) proteins. Traditionally, patients thought to be at risk of LS were referred for Clinical Genetics assessment and genome testing where applicable. Recently, screening strategies to streamline referrals have become popular in the UK, however, uptake of screening has been inconsistent with the local cost of testing being a limiting factor for many institutions. Design: We carried out a retrospective audit of all colorectal cancers which had undergone refl exive screening for LS in our institution in the year of 2013. All cancers meeting the modifi ed Bethesda criteria had been screened with immunohistochemistry (IHC) for MLH1, PMS2, MSH2 and MSH6 and those with a loss of MLH1/PMS2 expression had been (where funding was available) followed up with mutational analysis of BRAF V600E. Patients with negative IHC/BRAF were followed up in Clinical Genetics for further genetic testing. Results: 209 patients met the criteria for LS screening. 44 cases (21%) showed a loss in MLH1 expression and all but one of these cases showed concurrent loss of PMS2. BRAF V600E testing was carried out on 28 cases, only two of which were negative. IHC screening incurred a cost of $15,238 and BRAF testing incurred a cost of $5445. 18 patients were eligible for clinic referral at a cost of $15,758. Therefore, the total cost of LS screening was $36,452. Compared with traditional clinical follow up alone this gave a potential saving of $146,450. IHC screening alone reduced potential referrals from 209 to 45 at a saving of $143,509.
Refl exive Screening for Lynch Syndrome in the UK: An Audit and Cost-Effectiveness Analysis
Conclusions:
We have implemented LS screening within our institution at a signifi cant potential fi nancial benefi t. In line with national and international recommendations, LS screening not only brings improved patient care but brings local fi nancial savings and is increasingly recognised as a cost effective strategy for the National Health Service in the UK.
Comparing Fetal Tissue Procurement Methods on Quality of Karyotype Analysis
Joanna Conant, Mary Tang, Brenda Waters. University of Vermont Medical Center, Burlington, VT. Background: Chromosomal abnormalities are detected in up to 13% of all stillbirths and in over 20% of those with developmental anomalies. However, these estimates may be low since up to 50% of attempts to culture cells are unsuccessful due to microbial overgrowth or nonviability. Tissue for cytogenetics can be procured at bedside by the clinician or by the pathologist at autopsy. With clinical collection, tissue can be placed into culture media immediately, increasing chances of growth. However, tissue collection competes for attention with other activities, which may result in microbial overgrowth or selection of maternal rather than fetal tissue. Tissue obtained at autopsy is collected in a more controlled environment using sterile technique, but delay in procurement may decrease viability. The goal of this study was to determine which collection method yields better results. Design: This retrospective study reviewed cases from 2007-2013 that had two separate samples submitted for cytogenetics, one from the clinician and one from the pathologist. Medical records and cytogenetic culture sheets were reviewed for specimen source, time of delivery, collection time, setup time, harvest date, cell growth, microbial overgrowth, maternal contamination, and fi nal result. Results: More clinical than autopsy cases had microbial overgrowth. There was no difference in the number of cases with maternal contamination or signed out as incomplete or as no growth.
Conclusions: Our study demonstrated a significant increase in microbial overgrowth in clinician-procured samples. While there was a delay in the collection of tissue in pathologist-procured samples, there was no increase in the number of cases signed out as incomplete or as no growth. There was also no difference in the frequency of cases with maternal contamination between the two groups. These findings suggest that there may be benefit to collecting tissue for cytogenetics at time of autopsy rather than at bedside. Background: Paired-box (PAX) genes are a family of transcription factors involved in embryonic development and differentiation. PAX5 is expressed in neoplastic and non-neoplastic B-cells; PAX8 is expressed in normal kidney and in thyroid, renal, and Müllerian malignancies. PAX8 expression in lymphoid neoplasms is not well known. Rare studies report expression of polyclonal PAX8 in lymphoid proliferations due to high sequence homology between the N-terminus of PAX8 and PAX5. It is suspected that in B-cell neoplasms, antibodies with activity against the N-terminus of PAX8 will show positive staining due to cross reactivity. The goals of this study include evaluating the status of monoclonal PAX8 staining directed at the N-terminus (PAX8N), monoclonal PAX8 staining directed at the C-terminus (PAX8C), and to compare the results with PAX5 staining in the same lymphoid neoplasms. Design: PAX5 (Thermo Scientific, SP34), PAX8N (Ventana, MRQ-50), and PAX8C (Abcam, PAX8R1) expression was analyzed by immunohistochemistry on follicular lymphoma grades 1-3 (FL1, FL2, FL3), diffuse large B-cell lymphoma (DLBCL), small lymphocytic lymphoma (SLL), plasmacytoma, and anaplastic large cell lymphoma (ALCL). Expression was scored based on percentage of moderate to strong nuclear staining in neoplastic cells: 0=<5%, 1=5-25%, 2=26-50%, 3=51-75%, and 4=>75%. Results: In all neoplasms examined, PAX8N staining correlated with PAX5 and was strongly positive in all FL, DLBCL, and SLL. PAX8C was negative in all neoplasms examined. All PAX stains were negative in ALCL. Background: Given the increasing attention to cost control in health care, whether second-opinion pathology review objectively impacts patient care and treatment decisions remains controversial. We chose primary cutaneous melanoma as a model to address this question since surgical management and AJCC cancer staging of primary cutaneous melanoma is directed by the histopathologic parameters (e.g. Breslow thickness, ulceration, mitotic rate, satellitosis) of the lesion. We thus examined the relative rate of diagnostic changes that resulted in a change of stage and/or management of patients treated for primary cutaneous melanoma at our tertiary cancer referral center. Design: We performed a retrospective review of primary cutaneous melanoma diagnoses for 50 patients seeking surgical or medical consultation at our institution for the month of June, 2014. Major discrepancies were defined as a difference in diagnosis that would change patient stage and/or clinical management and were tabulated. Each case for which there was a discrepancy was reviewed by up to 5 dermatopathologists to achieve consensus.
Results:
We identified the rate of major discrepancies at 20% (10/50 cases) in this pilot study. The most common discrepancy (n=6 cases) was the identification of a dermal mitotic figure in a thin (≤ 1.00 mm) melanoma, resulting in a change of stage from pT1a to pT1b. At our institution, most patients with pT1b primary cutaneous melanoma are offered sentinel lymph node biopsy, whereas patients with pT1a lesions are typically not. In two of these cases, the patients presented to our institution with metastases. In addition, two discrepant cases originally diagnosed as melanoma in situ demonstrated dermal invasion upon re-review at our institution. Finally, second review of one case demonstrated multiple dermal satellite lesions in the excision specimen that were interpreted as part of the primary lesion by the referring pathologist. Based on the 2010 AJCC criteria, the presence of satellitosis dictates a pN2c (at least Stage IIIb), and the patient presented to our clinic with additional cutaneous metastases. The reasons underlying these discrepant opinions included both interpretation and tissue sampling. Conclusions: Second-opinion dermatopathology review (including consensus review for discrepant cases) changed the stage and/or management of 20% of patients with primary cutaneous melanoma at our institution and thus improves diagnostic accuracy to direct the most appropriate patient management. Design: H&E slides of all PNCBS received in a one month period were reviewed by two pathologists, with one blinded to the originating urology practice. Biopsies were assessed for histologic artifacts of poor preservation including: nuclear smudging and "halo" formation, especially of lymphocytes; cytoplasmic vacuoles; stromal cracking and retraction; and lack of hyperchromasia and nucleoli in prostatic carcinoma. PNCBS demonstrating at least one artifact were categorized as poorly fixed, and PNCBS lacking artifacts were categorized as adequately fixed. The source practice of each biopsy was then reviewed. One practice was identified as the source of poorly fixed PNCBS, and the Department of Urology was contacted via the HQC. Standard operating procedures (SOP) in all practices were reviewed to identify differences between the adequately and poorly fixed practices.
Results: Forty-two PNCBS were reviewed prior to intervention. Eighteen (43%) were poorly fixed, all from one referring practice. Consultation and investigation through the HQC revealed that PNCBS were placed on sterile water soaked sponges prior to formalin fixation, while the other practices used normal saline. No other differences were identified. The SOP in the practice with poor fixation was immediately changed to utilize normal saline instead of sterile water. To assess efficacy of the change, thirty-one consecutive biopsies sent following the change were reviewed in a blinded fashion. All biopsies were adequately fixed following intervention, including all 16 submitted from the practice with a history of poor fixation.
Conclusions:
The HQC facilitated a root cause analysis of a significant problem which led to a rapid improvement in PNCBS fixation. Resident-led quality assurance committees within hospitals can serve as a model for interdepartmental collaboration in resolving QA/QC problems while facilitating resident education. , 2012 (the "intervention"). A manual chart review was performed for patients with any positive results to see if the result was acknowledged in the medical chart. This study had Institutional Review Board approval as a retrospective study. Results: The serum paraneoplastic panel was ordered 279 times before the intervention (average: 6.8 panels/month) to 22 orders after the intervention (average: 1.47 panels/ month). There were multiple cases pre-intervention of duplicate testing for the same patient and of cases where results became available only after patients had expired or had been transitioned to hospice care. Before intervention, there were 65 panels with positive results (23% of total panels ordered) which were acknowledged in the medical record in only 38 of these patients (58% of positive results). After the intervention, there were 4 panels with positive results (18% of total panels ordered) which were acknowledged in the medical records in all 4 of these patients (100%).
The EMR can be a useful tool for limiting ordering of specialized and expensive laboratory testing. Based on our experience with one such test, the serum paraneoplastic autoantibody panel, such an intervention decreased the average number of tests ordered significantly, but without significantly changing the proportion of patients with a positive result. Furthermore, in a small sample size, the percentage of the time these results were acknowledged in the medical chart was increased. This would suggest that interventions of this type may help restrict the ordering of unnecessary tests, resulting in both cost savings to the hospital and the patient.
Validation of Digital Whole Slide Imaging According To the College of American Pathologists Guidelines in the Evaluation of Pre-Implant Kidney Biopsies
Albino Eccher, Anna Calio', Romano Colombari, Luigino Boschiero, Marilena Liviero Casartelli, Laura Zampicinini, Marco Chilosi, Claudio Ghimenton, Guido Martignoni, Matteo Brunelli. University and Hospital Trust, Verona, Italy; Ulss 20 Fracastoro Hospital, San Bonifacio, Italy. Background: We sought to validate the accuracy and quality of the digital medical devices for kidney biopsies during transplantation according to the College of American Pathologists guidelines. Design: Sixty-two histopathological cases from pre-implantation kidney biopsies were scanned by ScanScope Digital Slides Scanner (Aperio, Vista, CA) along 2013-2014 yrs. The diagnosis was performed by two pathologists of the call rota system during transplantation, on routine light microscopy, in order to quantify glomerulosclerosis, tubular atrophia, fibrosis and arteriosclerosis in accordance to the Remuzzi criteria. Both pathologists have a remote access to virtual slides from all the computers of the hospital via the viewer Web pocket with an user id. After two weeks, as wash out period, all slides were re-evaluated on computer devices. An overall assessment was obtained in a dedicated board room area to achieve concordance. Results: 124 whole glass slides were reviewed. Scan time averaged two minutes and 10 seconds per slide. The diagnostic score ranged from 2 to 8. After two weeks, side by side comparisons, between diagnosis performed on tissue glass slides versus pc widescreen were almost perfect (0,96 concordance) of intra-observer variability. All scores were confirmed by the same observer except for 5 slides (3 cases) which were upgraded at digitals for fibrosis and tubular atrophy, without changing the suitability for transplants. The inter-observer concordance between evaluation at glass slides and whole slide imaging was almost perfect (0,92) by the two pathologists. Other minor discrepancies were in the report of tubular acute necrosis features. The mean turnaround diagnostic time was respectively 15 min for glass slides and 18 min for digital slides.
Conclusions:
We validated the mode of digital score for pre-implantation kidney biopsies according to the College of American Pathologists guidelines. Digital pathology is adequate for primary diagnosis without delaying diagnosis to bridge temporal and geographic gaps between distant located pathologists involved in transplantation process. Furthermore the simple possibility of gathering a second opinion on a difficult case via digital device enhances the quality and safety of patient care.
Improving Next-Generation Sequencing (NGS) Success in Solid Tumors
Rashmi Goswami, Hui Chen, Keyur Patel, Mark Routbort, Hui Yao, Hyvan Dang, Bedia Barkoh, Ken Aldape, Sinchita Roy Chowdhuri, John Stewart, L Medeiros, Russell Broaddus, Rajesh Singh, Rajyalakshmi Luthra. University of Texas MD Anderson Cancer Center, Houston, TX. Background: Next generation sequencing (NGS) is important in the workup of solid tumors as genomic information becomes integrated into clinical practice. Performing NGS on solid tumors can be challenging due to the small size of biopsy specimens. Currently, there is little in the literature to indicate if manufacturer recommended NGS protocols can be improved to maximize the use of low DNA-yield specimens. The aim of this study was to determine if the manufacturer's DNA requirements (>0.85ng/uL) for the Ampliseq Cancer Hotspot v2 panel could be reduced, and still yield clinically useful results. Design: In a retrospective study of 614 consecutive solid tumor cases allocated to NGS, 67 (11%) cases were removed from the pipeline due to DNA yield <0.85ng/ uL. We tested 25 available cases with DNA <0.85ng/uL to determine if they could be successfully sequenced using the Ampliseq Cancer Hotspot v2 panel on the Ion Torrent PGM. Single gene confirmatory testing via Sanger or pyrosequencing was performed to confirm mutations discovered. In addition, a prospective study was performed on 408 consecutive cases collected from February 14-March 21, 2014. Cases were subjected to NGS analysis regardless of DNA concentration. We examined the NGS outcomes using previously identified characteristics such as selected tumor size and procedure types. Results: We demonstrated that NGS can be carried out on samples with DNA concentrations <0.85ng/uL. Of 25 cases, 17 (68%) were successfully sequenced (>300,000 reads with an AQ20 quality score). Of these, 13 cases showed mutations that could be tested using orthogonal methods, 8 of which were confirmed independently. The remaining cases could not be confirmed due to lack of DNA, poor PCR amplification/ Sanger sequencing quality, lack of primer coverage at the mutation site, and lower sensitivity of the orthogonal assay. For the prospective phase of this study, NGS success rates increased from 88% (the success rate in the retrospective phase with exclusion of cases <0.85ng/uL) to 95% (387/408). The gains were most pronounced among tiny (<10 mm2) biopsy samples (success rate from 76% to 94%) as well as cytology smears and cell blocks (success rate from 58% to 87%) (p<0.01). Conclusions: NGS can be successfully performed on cases using DNA concentrations less than the manufacturer's recommendations. This will expand the use of NGS in cases yielding minimal quantities of DNA including fine needle aspirates and tiny biopsies, allowing for the detection of clinically targetable mutations for patients with minute biopsies.
Insufficient Endometrial Sampling: Clinico-Pathologic Quality Assurance
Grzegorz Gurda, Esther Elishaev, Gloria Carter. University of Pittsburgh Medical Center, Pittsburgh, PA. Background: Endometrial sampling either a biopsy or curettage, are the first step procedure utilized for evaluation of endometrial status in order and to establish a definitive, tissue-based diagnosis of gynecologic disease. Unfortunately at times the tissue obtained may be insufficient or inadequate (InS/InA) for assessment. The management and clinical outcomes of these patients and the factors that influence the initial and subsequent endometrial sampling have not been well-studied. Design: A search of all patient records for 2003-2013 at University of Pittsburgh Medical Center was conducted via automated, de-identified TIES database tool. Sample data, general patient characteristics and pathology reports were retrieved in a blinded, automated fashion, then manually verified and analyzed. All-time and 1-year followup (F/U) procedure rates and clinical outcomes were tracked for all InS/InA samples. Results: A total of 1011 endometrial sampling procedures were identified over 10 years, comprising 2.0% of all such cases (total 52,137). InS/InA rate was similar on an annual basis (range 1.5-3.2%), but more frequent in July and August (beginning of the academic year, comprising 20% of total). InS/InA samples were more common among older patients (avg age 55.9 vs 49.5). Within 1 year, 41% of patients with InS/ InA had follow-up and 13% were again InS/InA and again more commonly among older patients (avg age 57.6). Among remaining 87% of patients: 89% showed benign F/U and 11% showed hyperplasia or neoplasia. For benign F/U cases a larger than expected 24% showed polyp(s) and a substantial 43% of cases with hyperplasia/ neoplasia showed a carcinoma. Conclusions: InS/InA diagnosis in endometrial sampling procedures is not uncommon, particularly among older population. Though on F/U most result in a benign diagnosis (often an endometrial polyp), a more advanced hyperplastic or neoplastic lesion occur in approximately 10% of the cases. The study also shows feasibility of de-identified database search tool to expeditiously create a large-scale quality assurance study, while offering best protection of patient heath information. Background: Currently pathology departments are mandated to perform review of frozen section diagnoses for discrepancies with the final diagnosis. Historically, this has been performed by manually collating printed reports and distributing them to faculty not involved in the final report of the intraoperative evaluation. The review was performed on a sheet of paper attached to the printed reports. We report our experience with developing an automated frozen versus final review activity. Design: A new activity was developed for our existing Laboratory Information Systems (LIS) CoPathPlus (Cerner, Kansas City, MO) that incorporated an electronic process instead of a paper form for completing frozen versus final diagnosis evaluation. The paper form included a signature line, date field, critical value assessment, number of frozen sections performed, number in agreement, diagnoses deferred, diagnostic discrepancies, and assessment for the adequacy of tissue submitted. Given the manual effort required to print and distribute packages for review as well as capture and organize the data, this process was automated to streamline the workflow. The LIS tool allowed cases to be assigned to designated pathologist worklists, the reviewing pathologist to electronically review the intraoperative diagnosis in direct relation to the final diagnosis, and have them complete their review using limited data fields with drop down menus.
Novel Tool To Streamline Frozen Section Versus Final Diagnosis Evaluation By Pathologists
Results:
The tool was deployed at one site; 54 cases with 73 reviews were completed in the first two months. The automated activity was well-received by faculty and the new activity was felt to be an improvement. The benefits realized by department and QA staff include automatic mechanism to assign cases to pathologists for review, less expensive process, and easier to perform statistics about frozen versus final diagnosis discrepancies. Conclusions: Pathology departments are required to review frozen section diagnoses for discrepancies. We developed and implemented an LIS-based tool to replace the manual paper-centric task of reviewing the frozen section diagnoses. The tool was well-received by pathologists and represents an improvement on our prior manual workflow for frozen section versus final diagnosis review.
2008 An Assessment of the Reliability of Platelet-Associated Flags Generated By the Sysmex XE-5000 Automated Hematology Analyzer Jennifer Hawkins, Gene Gulati, Guldeep Uppal, Jerald Gong. Sydney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA. Background: XE-5000 is an automated hematology analyzer utilized by clinical laboratories worldwide to perform CBC and differential leukocyte counts. The CBC results generated on some of the blood specimens are flagged by the analyzer for verification of the result of the flagged parameter. One such parameter of clinical significance is the automated platelet count, which is often unreliable if the blood specimen contains platelet clumps. We have determined the sensitivity and specificity of each of the three platelet-associated flags generated by this analyzer, with emphasis on its ability to flag for the presence of platelet clumps. Design: The CBC results of 200 selected blood specimens were retrospectively reviewed for the presence of analyzer-generated platelet-associated flags, which included the abnormal platelet size distribution or PAD flag, platelet clumps or CLP flag, and the large/giant platelets or LGP flag. One-half of the selected specimens were positive for platelet clumps by microscopic review and the remaining 100 were negative. The sensitivity was defined as the percentage of specimens revealing analyzer-generated flag among the morphologically positive cases. The specificity was defined as the percentage of specimens revealing no flag in the morphologically negative cases. Results: Among the morphologically positive specimens, 42 were flagged for the PAD, 57 for the CLP and none for the LGP, giving us the respective sensitivities of 42%, 57% and 0%. Among the morphologically negative specimens, 17 were flagged for the PAD, 1 for the CLP and none for the LGP, giving us the respective specificities of 83%, 99%, and 100%. The sensitivity did increase to 72% when a specimen was considered flagged for platelet clumps when either the PAD and/or the CLP flag was generated by the analyzer.
Conclusions:
The CLP has the highest sensitivity and the highest specificity, however, its sensitivity is below the desired level of 100%. Both, the sensitivity and specificity of the PAD flag are undesirably low. The LGP flag is expectedly insensitive to the detection of platelet clumps. To maximize the sensitivity to detect platelet clumps while maintaining the specificity, it is highly desirable for users of the XE-5000 analyzer to utilize the CLP flag along with an additional criteria of reviewing a blood smear on all new patients with a decreased platelet count and/or for the manufacturer of the analyzer to find ways to enhance the automatic detectability of platelet clumps.
Cost-Benefit Analysis of Routine Staining of All Lung Transplant Biopsies for CMV and Fungus in Anatomic Pathology
Ian Hughes, Stefan Pambuccian, Vijayalakshmi Ananthanarayanan, Swati Mehrotra. Loyola University Medical Center, Maywood, IL. Background: Lung transplant patients are at high risk of opportunistic infections. While the post-transplant infection rates have dropped dramatically with routine prophylaxis for CMV in seronegative patients and pan-prophylaxis for communityacquired infections, these patients must be judiciously monitored for infections and organ rejection. At our institution this involves transbronchial biopsy in conjunction with bronchialveolar lavage (BAL). Biopsies are processed with three H&E levels, Grocott methenamine silver (GMS) stain, and cytomegalovirus immunohistochemistry (CMV IHC). BAL specimens are subjected to a thorough laboratory work-up including fluid count, fungal smear, Pneumocystis carinii smear, fungal culture, quantitative bacterial culture, acid-fast bacilli (AFB) culture, 12-virus respiratory PCR panel, and 48-hour CMV PCR. When the economy necessitates review of current practices to stem the rising tide of healthcare costs, the utility of dual testing with CMV IHC and GMS stains on lung transplant biopsies seems increasingly questionable. In this study, our aim is to determine the frequency and clinical impact of positive CMV IHC/GMS cases and calculate the total cost of performing these tests. Design: Cases of transbronchial lung transplant biopsies were identified using a retrospective review of our database over the period from January 1, 2012 to June 17, 2014. A total of 463 cases were identified and evaluated in regards to GMS/CMV stain positivity and clinical significance. Conclusions: No cases were positive by CMV IHC. A single case showed fungal organisms by GMS stain, but review of this patient's biopsy specimen and clinical picture revealed the fungal elements to most likely be contaminant. Routine CMV IHC and staining for GMS on transbronchial transplant lung biopsies do not appear to offer any clinically significant information that isn't already derived from culture results or microbiologic studies. The cost incurred by our laboratories and charged to Medicare/ insurance companies over the period studied amounts to $201,827 or approximately $82,034 per year. Dual testing for these infectious agents by less sensitive methods seems to be a waste of health care dollars. Background: Microscopic examination of the routine three levels from bladder biopsies obtained from flat or papillary lesions identified in cystoscopy occasionally fails to identify a pathological lesion. However abnormalities may be found on additional deeper levels. The objective of this study is to assess the significance of deeper levels in bladder biopsies performed to diagnose papillary or flat lesions after routine levels are non-diagnostic as well as to revise the ideal number of levels which should be routinely examined in bladder biopsies in order to diagnose flat or papillary lesions encountered at cystoscopy. Design: 82 bladder biopsies performed at our institution (2012) (2013) were included in this study. The total number of levels in each case was recorded. The number of additional levels ranged from 3 to 9. The pathological diagnoses from all cases including papillary low grade urothelial carcinoma (PLGUC) or papillary high grade urothelial carcinoma (PHGUC) and urothelial carcinoma in situ (CIS) were correlated with the cystoscopic findings and with the additional deeper levels in order to reach a definite diagnosis. Each case had three standard levels (4 µm in thickness); according to our Laboratory Protocols (50 microns trimmed off the block before the next level).
Results: 31/82 (37.8%) cases required additional tissue levels (the number of additional levels ranged from 3 to 9). 21/31 (67.74%) of these cases were positive for malignancy including low or high grade papillary urothelial carcinoma. 85% of the cases required additional levels were noninvasive papillary UC (mainly low grade UC type) while 14% of the cases were invasive papillary carcinoma into lamina propria only and one case of carcinoma in situ. All of the 21 malignant cases had positive or suspicious cystoscopic findings. 10/31 (32.26%) cases were negative for malignancy and had negative or suspicious cystoscopic findings.
Conclusions:
In our study the initial three levels were non-diagnostic of approximately 37.8% (31/82) of the cases. 67.74% (21/31) of these cases had urothelial carcinoma which correlated with positive or suspicious cystoscopic findings. Based on these data, we realize that additional deeper levels are often essential in establishing an accurate diagnosis and therefore we suggest that the recommendation for the appropriate number of levels in bladder biopsies should be revised. Also an increase in the number of the initial levels should be reconsidered not only for accurate diagnosis but also to avoid tissue loss on re-cutting extra levels. Differences between institutions were analyzed by using the c2 test.
Results: A total of 19,524 breast cancer cases from 98 institutions were registered. The global mean proportion of positive cases was 17.16% (range: 9.5 to 32.5%). In metastatic cases, the HER2 average was 21.2%, while in non-metastatic cases was 16.9%. A total of 14 institutions (14.3%) were significantly out of range (p<0.05). These outlier institutions were related to poor results in external quality control program or to be referring hospitals in oncology with a large number of advance disease breast cancer patients. Conclusions: Although regular participation in proficiency testing and the existence of recommendations for HER2 testing significantly improved its performance in individual centers, quality assurance programs might be not sufficient to reduce interlaboratory variation, which became obvious using Confirma HER2 registry. This application allows to define the national rate of HER2 positivity in breast cancer and helps pathologists to be alerted about potential errors in laboratory assays, causative for over-or underestimation of cases suited for anti-HER2 therapy. The figure is a representative case in the severe necrosis category (70%) that had more than 2 somatic mutations. Conclusions: Clinical NGS testing was able to detect somatic mutations independent of % necrosis, up to a maximum of 80% tumor necrosis. This suggests that clinical analysis of tumors with more extensive necrosis may be feasible. This is especially relevant for colorectal adenocarcinoma, as the metastases are frequently associated with extensive necrosis. Design: 3 cases were captured prospectively in which CMV IHC stains were contaminated by single immunoreactive cells or small CMV positive clusters, presumably from the morphologically identical on-slide positive control. 2 were from patients with refractory inflammatory bowel disease on immunosuppressive treatment; CMV infection was clinically suspected in each. 1 was from an immunocompetent patient with chronic eosinophilia and dysphagia, and a biopsy with histological changes concerning for viral cytopathic effect. CMV IHC was performed on representative slides that contained both patient tissue and a positive control, using a cocktail of anti-CMV clones (CCH2/DDG9, 1:20; 8B1.2, 1:2000) and polymer-based detection after antigen retrieval.
Results: All cases contained detached CMV immunoreactive cells either on the patient tissue sample (above the plane of section) or loosely admixed with patient material.
Detached positive elements were also seen on the slide around or between separately mounted sections of the tissue ribbon. CMV positive elements were not present in or near patient material when IHC was repeated on additional tissue levels.
The contamination of patient material by detached CMV positive cells is uncommon, but raises concerns that the use of on-slide positive controls may eventually result in a false-positive result in a patient suspected of having clinically-relevant CMV infection. However, our cases also emphasize that careful evaluation of the patient material and areas adjacent to tissue, as well as assessment of the apparent plane of focus of IHC positive material, may mitigate this risk. Background: Six Sigma management can be defined as the relentless and rigorous pursuit of the reduction of variation in all critical processes to achieve continuous and breakthrough improvements that impact the bottom-line and/or top-line of the organization and increase customer satisfaction. According to The College of American Pathologists (CAP) "report signoffs on routine biopsy cases should be provided in a timely manner". Benchmark data defines "timely matter" to be a turnaround time (TAT) of not more than 2 working days. The current TAT of gastrointestinal (GI) small biopsies originating at the University of Miami Hospital Gastroenterology Clinic is 2.7 working days, which is higher than the industry standard. The aim of this project was to decrease the overall TAT while also improving patient, pathologist and clinician satisfaction. Design: The project was conducted by a multidisciplinary team including process improvement professionals, utilizing the Six Sigma DMAIC model (Define, Measure, Analyze, Improve and Control). First, the team studied the current state by mapping out processes, interviewing stakeholders, and collecting baseline data. Next, the team identified factors which caused the TAT to be problematic. The team then came up with solutions to mitigate the problematic factors and conducted several pilot tests to optimize the solutions. Finally the team implemented the new process full scale and sustained the changes via documentation and training.
Results: By applying interventions that included modification of the courier shifts, implementation of a third histotechnologist shift, the creation of quick texts for standardized diagnoses and Pathologist sign-out modifications, the TAT improved from a baseline of 2.7 working days to an average of 1.7 working days.
The application of process improvement methodologies, specifically the Six Sigma DMAIC model, to the Histology Laboratory setting helped to decrease the TAT of GI small biopsies from 2.7 working days to 1.7 working days, a 62% TAT reduction. In the opinion of the authors, the structured nature of the Six Sigma DMAIC methodology provides the rigor and discipline needed to create breakthrough process improvements in academic pathology settings. (9), cholangioca (1), met. NE ca (3), met. colon ca (1) and donor-derived small cell ca (1). Delivery system was known for 14 patients (7 TheraSphere; 7 SIR-Sphere). 4 patients received more than one (90)Y treatments. Resections were performed 3.8 -27mo after treatment (Therasphere 6.2-11.1mo; SIR-sphere 3.8-27mo), and included 8 explanted livers (7 native, 1 allograft), and 7 partial hepatectomies. All Therasphere-treated livers were radioactive upon receipt in lab; after RSP processing (upto 1wk) sections from 4 of these were radioactive in the histology lab. All 4 were treated 6.2 -7.6mo prior to surgery. No contamination was detected in the lab after processing was completed. All SIR-sphere treated livers were non-radioactive upon receipt in the lab. Conclusions: 1) Resected livers previously embolized with (90)Y may show detectable radioactivity. 2) Radioactivity is associated with TheraSphere treatment and a shorter duration between treatment and surgery. 3) Processing of (90)Y treated liver specimens under stringent RSP prevents contamination. 4) To our knowledge, this is the first report of protocol-based monitoring for liver specimens treated with (90)Y RE. These trends were comparable in the 3 separately studied clinical practices with one group showing nearly 90% reduction in their screening of women <21 years. While the majority (85%) of Pap test results were negative, most abnormalities were observed in younger women; in 2013, low-grade cytological abnormalities (ASC-US + LSIL) were reported in 20% of women <21 years screened compared to 4.5% of women >65 years. Conclusions: Our study demonstrates the awareness among community health providers of the 2012 ASCCP cervical cancer screening recommendations. The adherence to guidelines was best reflected in the <21 age group with significant reduction in the use of Pap tests.
Pap Test Utilization Trends in the Era of Changing Cervical Cancer
Evaluation of Intraoperative Frozen Section Discrepancies for Pancreatic Resections
Katherine Levinson, Stuti Shroff. University of Pennsylvania, Philadelphia, PA. Background: Positive resection margins in pancreatic adenocarcinoma (PA) and intraductal papillary mucinous neoplasms of the pancreas (IPMN) are associated with increased morbidity and mortality. Consequently, evaluation of pancreatic neck margins and bile duct margins for pancreaticoduodenectomy specimens and proximal pancreatic margin for distal pancreatectomy specimens are routinely performed as intraoperative consultation (IOC) to determine extent of surgery. With the advent of neoadjuvant therapy, IOC of these specimens is becoming increasingly difficult. Additionally, there are several confounding factors such as preoperative biliary stent placement that may make intraoperative interpretation of these specimens challenging. We evaluated pancreatectomy specimens to determine the variables associated with erroneus interpretation and identify methods to decrease discrepancies for margin assessment during IOC. Design: 112 consecutive pancreatectomy specimens received at the Hospital of the University of Pennsylvania over the course of one year (2013-2014) were reviewed. The following variables were studied: patient age/gender, histologic diagnosis and location of tumor, presence of pre-operative biliary stent placement, neoadjuvant therapy, and evaluation of margins by general surgical pathologists versus gastrointestinal pathologists. Results: Our study group consisted of 76 patients who underwent a pancreaticoduodenectomy and 36 patients who underwent a distal pancreatic resection. The most frequent diagnoses were 42-pancreatic adenocarcinoma (38%), 15-pancreatic endocrine neoplasms (14%), 13-pancreatic intraductal papillary mucinous neoplasms (12%) and 14-ampullary and duodenal neoplasia (13%). Intraoperative frozen section consultation was performed for 80 cases. Thirteen (11.6%) of these cases had discrepant IOC reporting at one margin (eight at pancreatic resection margin and five at bile duct margin). Of these, nine cases had interpretive errors and four were due to confounding factors (such as neoadjuvant therapy, 1, and evaluation of the bile duct margin post stent placement, 3). Ten (8.9%) discrepant cases were evaluated by general surgical pathologists at IOC and three (2.7%) evaluated by gastrointestinal pathologists. Conclusions: Our analysis suggests errors in IOC for pancreatectomy specimens can be avoided by obtaining history regarding neoadjuvant therapy and biliary stent placement. Errors in interpretation may also be decreased by consulting a gastrointestinal pathologist for challenging cases. 
Improving the Cost-Effectiveness of Specialized Testing for Bone Marrow Biopsies Using a Collaborative Algorithm-Based Approach
Results:
The average total costs per case, including molecular testing, FISH and chromosomal analysis, significantly decreased from $1112 of the pre-phase month to $1000 of the phase I and $727 of the phase II (Fig. 1A) . More dramatic cost savings were observed in the FISH tests with more than 50% reduction from pre-phase ($728) to phase II ($326). Between patients with unknown ( Fig. 1B) and known ( Fig. 1C ) diagnoses, there were more prominent decreases in the latter-mentioned patient population with $621 for total and $189 for FISH costs in phase II in comparison to $893 and $641 respectively in the pre-phase month. Given an estimated annual bone marrow volume of 400, the annual savings are estimated at $ 160,000. Conclusions: Hematopathologist-driven specialized test ordering with an algorithmbased system is a practical approach to optimize cost-effectiveness. Further assessment of quality and clinical satisfaction is necessitated to validate our approach.
Application of the Clinical and Laboratory Standards Institute EP23-A To Anatomic Pathology
Megan Lockyer, Daniel Grimmer. Baylor College of Medicine, Houston, TX. Background: As laboratory technology has become increasingly automated with system programs capable of assessing the results of a particular analyte for deviations from the mean and alarming when an outlying result is obtained, so too has quality control developed from a procedure for monitoring measuring system stability to a program of risk management. In the Clinical and Laboratory Standards Institute document EP23-A, the development of a risk management-based quality control program is outlined based on risk management procedures used and proven in industries for years. We applied the model described in EP23-A to create a risk-based quality control program for anatomic pathology. Design: We began by gathering information to create a process flow chart beginning with the acquisition of the specimen and ending with the final report being signed out. Once a complete process chart was established, we analyzed every step for possible failure modes. For each failure mode, we determined what possible impact it may have on the ultimate goal of correct specimen, correct patient and correct diagnosis. We then stratified the failure modes into low risk, intermediate risk and high risk depending on their impact. Once we identified all possible failure modes, we developed mitigations for the respective risks. The mitigations varied from education of housestaff to procurement of an automated barcode scanner system. We also outlined actions to be taken should a particular failure mode take place. Finally, we designed a dashboard for following errors with each error categorized based on the main components of our process. These included, but are not limited to, patient and/or specimen mislabeling, slide processing and turnaround time.
Results:
The comprehensive dashboard now serves as quality review at weekly departmental meetings and monthly interdepartmental meetings. It has allowed us to better evaluate when errors occur, why an error occurred and how we may decrease the liklihood of an error occurring again. Furthermore, the mitigations we developed have served to decrease errors in our laboratory.
Conclusions:
Risk-based quality control programs have been used in industries for years, and have been shown to be extremely effective. Following the same principles, EP23-A outlines how to create a laboratory quality control program based on risk management. We applied EP23-A to anatomic pathology, and created a quality control plan specific to our department allowing for continued identification, evaluation and mitigation of errors. Results: Of the 166 identified LEEP cases, 102 cases with HSIL diagnosis preceded LEEP were included in the study. Of these, LEEP confirmed 73 cases (71.6%) of HSIL while low grade or no SIL was found in 29 cases (28.4%). Re-review of the pathology material from the discrepant cases revealed that HSIL is reconfirmed in 18 cases (62.1%) while 11 cases (37.9%) were reclassified as non-HSIL. In the 11 reclassified cases, the original diagnoses included CIN2 (9 cases; 81.8%) and CIN3 (2 cases; 18.2%).
Correlation between pre-LEEP and LEEP specimens is an important quality assurance exercise for cervical excisions, similar to cytologic-histologic correlation required by CLIA 88. In the present study, majority of the discrepant cases had an initial diagnosis of CIN2, confirming the poorly reproducibility of this diagnosis. Given the complications associated with LEEP, particularly cervical incompetence in future pregnancy, supporting immunohistochemistry or concurrence by another pathologist should be considered prior to a diagnosis of CIN2. All cases coded as corrected, amended and supplementary were extracted from the NQAIS system for 2013. All corrected and amended reports and 571 consecutive supplementary reports (27% of total) were reviewed and the results were compared with the prior 2012 audit performed.
Results:
The addendum report rate for 2013 was 7.3% (24 amended, 116 corrected, 1895 supplementary reports). 20.7% (24/116) of corrected reports were re-categorised as amended and 2.8% (16/571) of supplementary reports were re-categorised as amended with 1.7% (10/571) re-categorised as corrected. This translates to a predicted departmental defect rate of 8.6/1000 cases and compares to a defect rate of 5.1/1000 cases for the previous year. The major defect rate (amended reports) was 4.1/1000 cases and the minor defect rate (corrected reports) 4.5/1000 cases. MDT discussion was the initiating factor in 66% (46/70) of amended reports issued (figure calculated post review of addendum reports). Conclusions: Continuous review of addendum reports is an important quality improvement monitor and should include review of all supplementary, corrected and amended reports to improve accurate categorisation and estimation of a departmental defect rate. The importance of peer review related to MDT discussion is also highlighted. . This approach often results in duplicate testing, particularly in the academic setting, where trainees may independently order IHC, and adds costs that may not be eligible for reimbursement based on the Medicare National Correct Coding Initiative. We aimed to establish a cost-effective diagnostic algorithm based on initial FC categorization to eliminate duplicate IHC marker usage.
Design:
We retrospectively reviewed 242 cases of suspected LPDs with concurrent FC and IHC testing over a 12-month period. We correlated FC with surgical diagnoses and evaluated the frequency of repeat IHC testing on concordant cases. Results: The most frequently repeated markers were CD3, CD5, CD10 and CD20 (Table  1) . Of concordant B-cell malignancies, 60% represented recurrent disease; however, this resulted in significantly fewer IHC stains only for cases of CLL (3.1 vs. 7 stains; p=0.04) despite accurate FC classification. FC did not reliably diagnose diffuse large B-cell lymphoma (n=50; 48% concordant). (14) 13 (93) 4 9 (70) n/a 5 (38) 9 (69) Mantle cell lymphoma (2) 2 (100) 7 2 (100) n/a 1 (50) 2 (100) Follicular lymphoma (35) 30 (86) (53) 25 (47) 9 15 (60) 18 (72) 20 (80) 21 (84) T-cell LPD (12) 7 (58) 11 6 (86) n/a 6 (86) 7 (100)
Conclusions:
We propose that, in de novo concordant cases, CD5 and CD10 should not be repeated by IHC; this would decrease use of these two commonly repeated IHC markers by an average of 79%. Furthermore, in recurrent cases, elimination of duplicate usage of CD3 and CD20 in addition to CD5 and CD10 would reduce IHC-associated costs by an average of 61%. Finally, we show that FC reliably characterizes benign entities and, when considered along with morphology, may constitute a sufficient immunophenotypic work-up for such cases. Background: Turnaround time (TAT) is an important metric for pathology laboratories as it pushes the system to provide services in a time that is as optimal as possible for patient care. In our institution, the time of signout of complex surgical cases of malignant neoplasms historically was relegated to the last cases processed by the histology laboratory. In recent years, the emergence of multidisciplinary tumor boards where oncologic patient management is decided is commonplace and pathology evaluation of the patient's specimen is a cornerstone. Making the pathology report of these large and complex cases available as soon as possible speeds management decisions. Design: In an effort to improve TAT for large cases that would be presented in weekly multidisciplinary oncology planning conference tumor boards. We re-prioritized the order of cases coming out of the histology laboratory. We maintained as first priority biopsy specimens that were requested to be emergent by the clinician or cases in which a tumor was biopsied. Subsequently, surgical oncologic cases were available. Following these cases, biopsies judged less urgent were cut and stained. To evaluate the change in TAT (time from specimen accessioning to reporting of results), we compared the TAT data based on CPT codes of 88307 and/or 88309 extracted from laboratory information system (Cerner, Kansas City, MO) for the 6 months period (Jan-June 2014) after implementation of changes with TAT data from 11 months prior to changes (Jan-Nov 2013). The analysis was performed in Microsoft Access and Excel 2013 (Microsoft, Redmond, WA). Results: The average TAT for 2388 large cases from first half of 2014 (Jan-June) improved to 3.40 days (95% CI 3.30-3.50 days) as compared to a TAT of 3.98 days (95% CI 3.86-4.11 days) for 4748 large specimens in 2013 (Jan-Nov). The absolute TAT for large specimens decreased by 15% (p-value <0.01). Counting days, the decrease was 0.58 days. Cases requiring immunohistochemical staining or additional submission of histology blocks was much more easily accomplished on all large cases as these activities were performed much earlier in the work day. Handling complex cases earlier also resulted in increased resident and faculty satisfaction. Conclusions: Rearranging the priority of surgical cases such that large tumor resection cases are entered into the workflow earlier has resulted in decreased TAT for these cases, allowing more cases to be presented at weekly tumor boards and has increased satisfaction amongst pathologists.
Expectation-Interpretation Mismatch: Lack of Standard Definitions for Histology Lab Terms and Resulting Implications for Workflow and Patient Care
Whitney McCarthy, Jason Moss. Baylor College of Medicine, Houston, TX. Background: Pathologists (PTs) requesting additional H&E-stained slides often use terms such as recut, level, and deeper, which must be interpreted by histotechnologists (HTs). Our prior single institution survey regarding usage of these terms showed marked disagreement between and among PTs and HTs, potentially increasing PT turn-around time and HT workload, and raising the possibility of unsampled lesions in the block. To gain further insight into this issue, a survey was distributed to PTs and HTs at several of our affiliated institutions. Design: A survey with twelve open-ended questions (e.g., tissue section thickness, number of sections discarded between slides, definitions for recut, level, and deeper) was distributed to 50 PTs and 32 HTs at five affiliated institutions. Results: 1. Survey response rate: 78% PTs, 69% HTs 2. Average section thickness (by institution #s 1-5): PTs: 3.9 mm, 4.1 mm, 5.2 mm, 4.3 mm, 4.5 mm HTs: 3.2 mm, 5.0 mm, 3.7 mm, 3.7 mm, 3.8 mm 3. Average number of sections discarded between levels (by institution #s 1-5): PTs: 3.4, 2.0, 4.6, 7.7, 5.5 HTs: 3.7, 6.0, 2.0, 1.3, 4.2 4. Average number of sections discarded between deepers (by institution #s 1-5): PTs: 6.0, 7.5, 8.3, 11.7, 6.5 HTs: 7.3, 15.0, 4.0, 2.5, 9.7. Conclusions: 1. This multi-institution study reinforces the findings of our prior single institution study, which found PTs and HTs have a marked disagreement in their definitions of recut, level, and deeper. 2. Non-standardized definitions for these terms may lead to an expectation-interpretation mismatch between PTs and HTs, resulting in: a. Repeat requests for additional sections and increased HT workload/PT turn-around time. b. Tissue sampling that is inadequate or inappropriately deep (Fig. 1) . 3. Rather than using qualitative, subjective definitions for these terms, quantitative standards should be developed. Further investigation and communication between PT and HT professional organizations will be needed to reach a consensus.
Frozen Section: Guiding the Hands of Surgeons?
Eleanor McIntosh, Joseph Drwiega, Margaret Brandwein-Gensler, Shuko Harada, Jennifer Gordetsky. University of Alabama, Birmingham, AL. Background: Intraoperative frozen section (FS) analysis is a powerful tool that can provide a rapid diagnosis, thereby directing operative management. However, FS can also be misused. We consider a FS to be "inappropriate" when it does not influence operative management. One example is sending a FS to allow the surgeon to provide reassurance, or convey an early diagnosis to the patient or family. Inherent in this action is a failure to acknowledge the limitations of a "preliminary diagnoses". Not only can inappropriate FS compromise limited diagnostic material, they can impact turn-around-time of other appropriate FS submitted simultaneously. The objective of our study was to evaluate the utilization of FS at our institution and assess influence on operative management. Design: Our pathology database was searched from December -June of 2013 for FS cases, which were then stratified by surgical subspecialty. Operative, clinical, and pathology notes were reviewed to determine the rationale for sending each FS and to determine its impact on operative management. Cases lacking operative notes were excluded from this study. Results: 2165 FS were performed in 1057 surgical cases; the average number of FS per case was 2. Surgical subspecialties that utilized FS included cardiothoracic, otolaryngology, breast, surgical oncology, gynecology, gastrointestinal, hepatobiliary, urological, transplant, and orthopedics. 41% of FS evaluated margin status, 35% confirmed or excluded malignancy, 11% were for tumor classification, 6% assessed adequacy for diagnosis, 3% were to confirm or exclude infection, 3% were for transplant, and 2% were for lymphoma workup. We found that 12% (259/2165) of FS did not influence operative management. This was most common among cardiothoracic surgeries (34%). No "inappropriate" FS were sent for any transplant or orthopedic surgeries. ENT utilized the most FS and had <1% that were "inappropriate".
Conclusions:
At our institution, the majority of FS influence operative management, with margin assessment being the most common scenario. The rationale for sending a FS and its influence on operative management was highly subspecialty dependent. Interdepartmental discussions on FS utilization might be helpful in the elimination of unnecessary FS.
Delayed Autopsy Reporting -A Self Study and Root Cause Analysis
Stephanie Moss, Caroline Alquist, Robin McGoey. Louisiana State University Health Sciences Center, New Orleans, LA. Background: The medical autopsy at our teaching institution is a multi-step procedural process aimed at understanding disease processes that contribute to a patient's death. Correlation with ante mortem lab and clinical data is required both prior to and following the procedure. Both gross and microscopic analyses of every organ system are conducted and lab studies such as cultures and toxicology are frequently ordered. The final autopsy protocol averages 7-10 pages and includes documentation of findings from every step in the process. Approximately 180-240 cases are performed per year by the service. Design: In response to a citation issued by the College of American Pathologists (CAP) regarding delayed autopsy reporting, the autospy service launched a resident-initiated root cause analysis (RCA) and self-study in order to identify the contributing causes for delayed reports and to design workflow efficiencies and process improvements such that turnaround time was monitored, tracked and improved. Focused interviews were conducted with all of the residents, staff and faculty involved with the service. Data on all case turnaround time from 2011-2013 (n=656) was calculated. Results: The average turnaround time was 80 (2011), 85 (2012), and 89 (2013) . The CAP standard requires 90% of cases finalized within 60 working days. Our service completed 22-42% of cases within 60 working days. The focused interviews with residents and faculty clearly identified areas of significant delay. Objective review of data including log books and histology tracking records substantiated some of the perceived areas of delay while clearly refuting others. The incorporation of a monitoring system and elimination of redundancy in workflow processes significantly improved turnaround time of reports. To date, the average turnaround time in 2014 is 36.3 days with 93.3% of cases finalized within 60 working days. Conclusions: RCA and self-study analyses are effective methods for elucidating both real and perceived barriers to efficiency in the workplace yielding a better understanding of the organizational culture and its openness to change. As a result of the RCA on delayed autopsy reporting, corrective actions were proposed to the CAP and implemented into the autopsy service. The measurable outcome has been better compliance with the autopsy reporting standard and a system in place for tracking turnaround time compliance. Moreover, an added outcome of earlier reporting of autopsy findings will undoubtedly be better quality of care and communication of post mortem findings to the clinical care team. Previously a 2+ staining pattern on IHC, indicating an equivocal test, was described as complete membrane staining in >10% but <30% of cells. The updated guidelines define a 2+ as incomplete or weak membrane staining in >10% of tumor cells (low 2+) or complete membrane staining in < 10% of cells. These guidelines, however, did not discuss the utility of ACIS, and recommend the utility of FISH in these low 2+ HER2 breast carcinomas. Our goal was to identify the necessity for FISH in those cases with the low 2+ pattern and those stratified by ACIS IHC results. Design: All breast carcinomas that were rated by visual IHC as incomplete staining in >10% of tumor cells (low 2+ pattern) were collected from February to September 2014. These were analyzed by Automated Cellular Imaging System III (ACIS) (DAKO) and scored as the mean of 6 areas with a 40x objective. Scores of 0.4-1.7 were graded as 0-1+ (not expressed), 1.8-2.6 as 2+ (equivocal), and above 2.6 as 3+ (overexpressed).
CAP/ASCO
FISH for HER2 amplification used the PathVysion HER2 DNA probe kit (Abbott Molecular). Interpretation of the HER2/centromere 17 ratios for the FISH were per the CAP/ASCO guidelines. Results: A total of 28 cases of low 2+ HER2 were included. Tables 1 and 2 demonstrate the visual and image cytometric scores compared to HER2 FISH, respectively. In 24 (85.7%), visual IHC and FISH results were concordant (negative, non amplified). In 20, ACIS IHC <1.8 and FISH results were 100 % concordant (negative, non amplified). None of the HER2 FISH on the 28 cases was amplified. Background: While guidelines exist regarding key elements of molecular pathology reports, there is little data available assessing real world compliance. In this study we investigate how laboratories report molecular tests using the BRAF College of American Pathologists (CAP) proficiency testing as a mock patient sample report. Design: Laboratories subscribing to the CAP BRAF proficiency test were asked to submit a full mock patient report based on the sample. The reports were de-identified at CAP and the data were abstracted by two members of the CAP Molecular Oncology Committee. Variables recorded included basic elements (methodology, specimen source, etc) and elements specific to molecular diagnostics (gene nomenclature, specific assay target, etc) derived from CAP checklists and published guidelines on molecular reporting (Gulley et al. Arch Pathol Lab Med 2007; 131:852-863) . Results: 62 laboratories participated. The CAP checklists require correct gene nomenclature: none of the surveyed used the full HUGO gene name but all provided the correct gene symbol. 100% listed a test methodology, while 53 (85.6%) also specified the method target. 34 (54%) included an interpretive comment. None of the reports listed the required percentage of malignant cells. Limit of detection (LOD) and performance of dissection are not specifically required in current guidelines, but were tracked in this study. 44 (71%) reports included LOD with majority (73%) claiming between 1-5% LOD. 8 (13%) reports specified performance of dissection. Conclusions: Molecular tests have specific reporting necessary elements to ensure appropriate interpretation. The results of the present study indicate that the majority of laboratories include required elements including specific target and methodology, while only half include an interpretive comment. Some report components are not yet required (LOD and dissection) and are currently provided by a subset of laboratories.
Limitations of the study include difficulty in generalizing BRAF data to other molecular tests, as well as responder bias to this voluntary survey. These preliminary data suggest that updated guidance should be provided regarding an adequate molecular pathology report, including possibly requiring relevant data elements such as LOD and dissection in future guidelines. Vamsi Parimi, Julianne Ubago, Yelda Orhan, Megan Sullivan, Stephen Rohan, Michael Balco, Robert Chatterton, Piotr Kulesza, Demirkan Gursel, Jian-Jun Wei. Northwestern University, Chicago, IL. Background: Independent inter and intra observer review and single field of view (FOV) with multi-reviewer evaluation methodologies are not studied well in context to reviewer concordance. We conducted assessment study of inter and intra observer variation among tissue based biomarker evaluation by immunohistochemistry and insitu mRNA. Various variables like scoring criteria, simplicity of criteria, number of classification tiers, heterogeneous biomarker expression and sampling regions that may influence the inconsistencies among observers are evaluated in this study. Design: To examine observer agreement, twelve biomarkers as part of 50 studies with nuclear, cytoplasmic and membranous localization stained on whole slide and tissue microarray were evaluated independently by multiple pathologists and pathologists in training. Nuclear biomarkers Ki67, p53, ER and PR were evaluated by percentage of positively stained nuclei in tumor cells of interest. Similarly biomarkers expressing cytoplasmic staining are evaluated by 4 tier system and H-Score (composite) which accounts for percentage of cell stained at low, moderate to high intensity. Membranous staining for Her-2 neu expression is performed by ASCO/CAP guidelines. Insitu mRNA transcript density review was also conducted. The intra observer evaluation was performed with 20 day washout period to reduce recall bias. Pearson's concordance correlation was calculated among respective observers.
Inter and Intra Observer Concordance of Tissue Based Biomarkers in Pathology
Results:
The results of our study show wide range (-0.06 to 0.95) of concordance among observers with glass slide evaluation. Biomarkers localized to nucleus had the highest concordance among inter and intra observer evaluation compared to membranous and cytoplasmic stains.
Conclusions:
Nuclear biomarker evaluation has the highest concordance rate among independent reviewers. Simplified scoring criteria with low tier system showed higher concordance. (13%) were affected by an image flaw upon initial scanning. The vast majority of these flaws were out-of-focus areas (95% of flawed slides). Other flaws included truncated images (3% of flawed slides) and absent images (0.4% of flawed slides). Of the out-of-focus images, most (66%) had no apparent underlying root cause, but in the remainder (34%), the problem was due to artifacts or poor FS quality, including air bubbles (23%), thick/ uneven sections (6%), tissue fragmentation (2%), and folded sections (2%). Of the 224 rescanned slides, flaws were completely corrected in 97 slides (43%) and partially corrected in 23 slides (10%). For 92 slides (41%), the problem remained the same, and in 12 slides (5%) the problem worsened. However, in only one case (0.18% of all cases) did the severity of the image flaw render the case non-diagnostic. Conclusions: Whole-slide digital imaging of FSs with a Philips platform yields diagnostic-quality images in the overwhelming majority of cases. In a significant proportion of flawed images, artifacts introduced during FS preparation were the root cause, emphasizing the need for high-quality FSs intended for WSDI. For each IHC score category, the HER2/D17Z1 ratio range, mean and number of cases with a ratio of > 2.2 (considered HER2 amplified) were determined. Results: 341 patients positive for ANA at 1:40 only were found; 182 had available EMR records and were included in the study. Median age was 48 (5-90) and the F:M ratio was 3.7:1. Only 7 (3.8%) new diagnosis of AICTD were made (2-SLE, 2-Sjögren's syndrome, 2-Unspecified, 1-Polymyalgia Rheumatica). 22 patients (12.1%) had a previous diagnosis of AICTD. Non-autoimmune diseases were diagnosed in 116 cases (63.7%) including skeletal-muscular (66), Neurological-psychiatric (11), viral-related (7), renal (5) and dermatological (4). In 6 cases the ANA result by itself prompted an unnecessary referral to rheumatology. Of the 7 new cases of AICTD abnormal additional testing was identified in 5 cases.
HER2 Status in Gastroesophageal Adenocarcinomas
Conclusions:
In the present study, ANA at 1:40 was found useful in only 7 cases (new diagnoses of AICTD) with a significant proportion of patients having false positives (116/145) results. A case for increasing the cut-off titer for a screening ANA can be made considering the wasted resources and additional anxiety caused in patients. In 83 cases unnecessary reflex ENA ($17 each) was ordered. On the other hand, with the proposed higher cutoff value 7 true cases of AICTD might have been missed with potential harm to patients. Further studies are required to help define better cutoff titers that could perhaps be different according to the demographic characteristics of the patients as some studies have suggested. Jennifer Sehn, David Spencer, John Pfeifer, Catherine Cottrell, Haley Abel, Andrew Bredemeyer, Eric Duncavage. Washington University, St. Louis, MO. Background: Specimen provenance errors (SPE) are known to occur in laboratory testing and are a potential source of misdiagnosis and suboptimal patient management. Due to complex workflows involved with clinical next-generation sequencing (NGS) assays, it is likely that SPE are also an issue in NGS testing. Because NGS methods are used to identify and report variants present at variant allele frequency (VAF) of 10% or lower in clinical testing of cancer samples for tumor genetic profiling, it is critical to quantitate the degree of specimen contamination in NGS data, particularly since reported variants can be used as a basis for patient management decisions. CAP and ACMG guidelines for molecular testing stipulate the need to assure that patient specimens are not contaminated during laboratory testing, but the means for doing so
Specimen Contamination in Clinical NGS Data
are not yet established for NGS assays. Design: Using a haplotyping approach for identity determination with orthogonal validation by short tandem repeat (STR) analysis, we sought to determine the rate of clinically significant (≥5%) DNA contamination in clinical NGS data from 296 consecutive cases. Haplotype analysis was performed by identifying the number of HapMap-derived haplotypes that were present at closely spaced (within a single sequenced DNA fragment) SNP pairs that were present in the genomic regions targeted by the clinical assay. Percent admixture was estimated based on the VAF of minor haplotypes across multiple loci. Results: We identified 9 cases (3%) with >5% admixture of the sequenced DNA as determined by haplotype and STR analyses. Three cases were from bone marrow transplant patients who were known to be chimeric. DNA yields for 5 cases were suboptimal (110-450 ng, where 1,000 ng is the preferred amount for clinical sequencing). One case yielded 1,340 ng of DNA but was contaminated during tissue collection from the block or DNA extraction, based on stepwise STR testing. In all, 10.9% of cases with DNA yield <500 ng and 21.4% of cases with DNA yield <200 ng were contaminated by the criteria used in this study (p=0.01 and p=0.003, respectively).
Conclusions: Specimen contamination with foreign human DNA occurs in clinical NGS testing. Tools for detecting contamination in NGS sequence data must be integrated into clinical bioinformatics pipelines to prevent reporting of potentially actionable variants in patients whose tumors do not actually harbor those variants, especially as laboratories tend toward using smaller amounts of input DNA and reporting lower frequency variants. Results: A total of 179 patients were identified that fulfilled the above conditions. Granulomas were identified in 47 patients: 79% had non-necrotizing granulomas, 11% had necrotizing granulomas, 10% had nonspecific granulomatous inflammation. Of the patients with clinical suspicion of sarcoidosis and non-necrotizing granulomas, 62% had ZN and GMS stains performed on the cell block material; 100% of these were negative for infectious organisms. Only 3% of concurrent cultures were positive. Conclusions: Though histochemical stains were performed in the majority of patients with clinical/imaging suspicion or confirmed history of sarcoidosis, lack of positive histochemical stain results suggests that these tests may have been unnecessary. In addition, concurrent cultures were largely negative. The results suggest that histochemical organism stains in this patient population may be unnecessary when non-necrotizing granulomas are identified in the cell block material.
Errors in Gynecological Frozen Section Consultations
Thomas Stockl, Laura Goddard, Yuxin Liu. UMass Memorial Medical Center, Worcester, MA. Background: Intraoperative consultations play an important role in management during gynecological surgeries. Pathologists must make appropriate judgments regarding what tissue to sample, make an accurate interpretation of the selected frozen section and effectively communicate those findings in order to guide decisions regarding the extent of surgery. Error during any part of this process may result in significant adverse outcomes for the patient. Correlation of frozen section diagnosis with permanent sections is an integral component of laboratories' quality assurance (QA) programs and provides an opportunity to reduce future adverse outcomes. The aim of our study was to identify specific sources of error leading to discordant frozen section diagnoses of gynecologic lesions. Design: All gynecological frozen sections performed between 2009 and 2013, excluding metastases from non-gynecological primary sites, were selected and the pathology reports were reviewed for concordance between frozen section and final diagnoses. Cases were reviewed for histologic classification, grade and whether subsequent staging surgery was performed. The slides for discordant cases were further reviewed at QA meetings and a consensus root cause of error was determined. Results: Discordant findings between frozen section and final reports were identified in 118 of 1419 cases (8.3%). The cause of discordance was attributed to sampling error in 84% of the cases and interpretive error in the remaining 16%. The two most common scenarios for sampling error were 1) cases where the endometrium was interpreted as negative or atypical hyperplasia on frozen section and found to be endometrial adenocarcinoma (generally microscopic and low grade) on final sections (48 cases) and 2) grading of endometrial adenocarcinoma (25 cases). Discordance was not associated with subsequent staging (p = 0.18) however, it was associated with tumor category (i.e. benign vs. malignant) as a greater proportion of discordant cases were malignant compared to concordant cases (p < 0.0001).
Conclusions:
The majority of discordant frozen section diagnoses indentified in our analysis resulted in little or no significant clinical consequence; however, rare cases were identified in which operative management was not optimal due to either sampling or interpretive error. Careful gross examination of specimens to optimize sampling is of paramount importance. Nevertheless, pathologists and surgeons should have a mutual understanding of the limitations of the frozen section. Consensus review of cases as part of a QA program serves as an effective means of learning from past errors.
